Cargando…
Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis
Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analys...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239593/ https://www.ncbi.nlm.nih.gov/pubmed/35777041 http://dx.doi.org/10.1097/MD.0000000000029806 |
_version_ | 1784737332614660096 |
---|---|
author | Shen, Nirui Wang, Qingting Qiu, Yuanjie Wang, Yan Li, Danyang Li, Manxiang |
author_facet | Shen, Nirui Wang, Qingting Qiu, Yuanjie Wang, Yan Li, Danyang Li, Manxiang |
author_sort | Shen, Nirui |
collection | PubMed |
description | Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analysis to evaluate the prognostic and clinicopathological significance of ROC1 in patients suffering from cancer. METHODS: We searched Pubmed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database. The role of ROC1 in cancers was evaluated by pooled hazard ratios (HRs), odd ratios (ORs) and 95% confidence intervals (CIs). RESULTS: In total, 9 studies including 1002 patients were enrolled in this analysis. The pooled results showed that patients with high expression of ROC1 had poor overall survival (OS) (HR: 2.04, 95% CI: 1.48–2.60, P < 0.001) and recurrence-free survival (RFS) (HR: 1.727, 95% CI: 0.965–2.488, P < 0.001). Additionally, elevated expression of ROC1 was significantly correlated with advanced clinical Tumor Node Metastasis stage (OR: 2.708, 95% CI: 1.856–3.951, P < 0.001), positive lymph node metastasis (OR: 1.968; 95% CI: 1.294–2.993, P = .002), large tumor size (OR: 1.522, 95% CI: 1.079–2.149, P = .017) and poor tumor differentiation (OR: 2.448, 95% CI: 1.793–3.344, P < 0.001). CONCLUSIONS: Elevated ROC1 expression predicted worse prognosis and advanced pathological parameters in various cancers. ROC1 was a significant prognostic biomarker for poor survival in human cancers. |
format | Online Article Text |
id | pubmed-9239593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-92395932022-06-30 Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis Shen, Nirui Wang, Qingting Qiu, Yuanjie Wang, Yan Li, Danyang Li, Manxiang Medicine (Baltimore) Research Article Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analysis to evaluate the prognostic and clinicopathological significance of ROC1 in patients suffering from cancer. METHODS: We searched Pubmed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database. The role of ROC1 in cancers was evaluated by pooled hazard ratios (HRs), odd ratios (ORs) and 95% confidence intervals (CIs). RESULTS: In total, 9 studies including 1002 patients were enrolled in this analysis. The pooled results showed that patients with high expression of ROC1 had poor overall survival (OS) (HR: 2.04, 95% CI: 1.48–2.60, P < 0.001) and recurrence-free survival (RFS) (HR: 1.727, 95% CI: 0.965–2.488, P < 0.001). Additionally, elevated expression of ROC1 was significantly correlated with advanced clinical Tumor Node Metastasis stage (OR: 2.708, 95% CI: 1.856–3.951, P < 0.001), positive lymph node metastasis (OR: 1.968; 95% CI: 1.294–2.993, P = .002), large tumor size (OR: 1.522, 95% CI: 1.079–2.149, P = .017) and poor tumor differentiation (OR: 2.448, 95% CI: 1.793–3.344, P < 0.001). CONCLUSIONS: Elevated ROC1 expression predicted worse prognosis and advanced pathological parameters in various cancers. ROC1 was a significant prognostic biomarker for poor survival in human cancers. Lippincott Williams & Wilkins 2022-06-30 /pmc/articles/PMC9239593/ /pubmed/35777041 http://dx.doi.org/10.1097/MD.0000000000029806 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | Research Article Shen, Nirui Wang, Qingting Qiu, Yuanjie Wang, Yan Li, Danyang Li, Manxiang Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis |
title | Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis |
title_full | Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis |
title_fullStr | Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis |
title_full_unstemmed | Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis |
title_short | Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis |
title_sort | clinicopathological and prognostic role of roc1 in neoplasms: a prisma-compliant systematic review and meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239593/ https://www.ncbi.nlm.nih.gov/pubmed/35777041 http://dx.doi.org/10.1097/MD.0000000000029806 |
work_keys_str_mv | AT shennirui clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis AT wangqingting clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis AT qiuyuanjie clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis AT wangyan clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis AT lidanyang clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis AT limanxiang clinicopathologicalandprognosticroleofroc1inneoplasmsaprismacompliantsystematicreviewandmetaanalysis |